A phase I study of two different schedules of nab-paclitaxel (nab-P) with ascending doses of vandetanib (V) with expansion in patients (Pts) with pancreatic cancer (PC).
A. B. El-Khoueiry
Consultant or Advisory Role - AstraZeneca
S. Iqbal
No relevant relationships to disclose
H. Lenz
Consultant or Advisory Role - Abraxis BioScience
B. J. Gitlitz
No relevant relationships to disclose
D. Yang
No relevant relationships to disclose
S. Cole
No relevant relationships to disclose
V. Duddalwar
No relevant relationships to disclose
A. Garcia
No relevant relationships to disclose